Fenofibrate use in adults with type 2 diabetes (T2D) is linked to a reduced risk of developing sight-threatening diabetic retinopathy (STDR) compared to statins in a large UK real-world cohort.
The beneficial association of fenofibrate was consistent across multiple subgroups and sensitivity analyses, with a more pronounced effect in intention-to-treat and per-protocol settings.
Notably, the protective effect of fenofibrate was not observed in South Asian patients, indicating potential ethnic differences in response.
